ANGLE plc (id:3988 AGL)

10.50 GBP

Opening hours: 08:00 - 16:30 (GMT Standard Time: 11/22/2024 5:48:46 PM)

Exchange closed, opens in 2 days 14 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• 5 years
• 10 years
• All

About ANGLE plc

Market Capitalization 37.09M

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use its proprietary pan-cancer next generation sequencing (NGS) panel. The company was founded in 1994 and is based in Guildford, the United Kingdom.